RE: presentation5 Dec 2019 01:23
TW write up concludes.....
We previously noted, with full contribution and cost benefits from the Elucigene acquisition, there are hopes for £10 million+ of second half revenue and breakeven being delivered and we’ve noted broker forecast of a profit heading towards £2 million next year on revenue above £21 million though that the company’s trading momentum sees us consider that could well prove conservative.
We’ve also previously noted a hybrid DCF analysis and peer-based EV/sales multiple valuation of 20p per share. The operational progress sees us continue to target 17p+ to sell for the shorter-term purposes of this website and, at around 13p, buy.